160 related articles for article (PubMed ID: 11295289)
1. Decreased topoisomerase IIalpha expression confers increased resistance to ICRF-193 as well as VP-16 in mouse embryonic stem cells.
Kobayashi M; Adachi N; Aratani Y; Kikuchi A; Koyama H
Cancer Lett; 2001 May; 166(1):71-7. PubMed ID: 11295289
[TBL] [Abstract][Full Text] [Related]
2. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
3. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
4. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
5. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
6. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
7. Ectopic expression of human topoisomerase IIalpha fragments and etoposide resistance in mammalian cells.
Ernst AI; Soltermann A; Sigrist JA; Widmer L; Gasser SM; Stahel RA
Int J Cancer; 2000 Oct; 88(1):99-107. PubMed ID: 10962446
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
9. Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.
Davies SL; Bergh J; Harris AL; Hickson ID
Br J Cancer; 1997; 75(6):816-21. PubMed ID: 9062401
[TBL] [Abstract][Full Text] [Related]
10. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
11. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
12. Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells.
Akimitsu N; Kamura K; Toné S; Sakaguchi A; Kikuchi A; Hamamoto H; Sekimizu K
Biochem Biophys Res Commun; 2003 Jul; 307(2):301-7. PubMed ID: 12859955
[TBL] [Abstract][Full Text] [Related]
13. Expression of drug resistance genes in VP-16 and mAMSA-selected human carcinoma cells.
Matsumoto Y; Takano H; Kunishio K; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Jul; 92(7):778-84. PubMed ID: 11473729
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
15. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Ogiso Y; Tomida A; Lei S; Omura S; Tsuruo T
Cancer Res; 2000 May; 60(9):2429-34. PubMed ID: 10811120
[TBL] [Abstract][Full Text] [Related]
17. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
18. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
[TBL] [Abstract][Full Text] [Related]
19. Induction of resistance to etoposide and adriamycin in a human glioma cell line treated with antisense oligodeoxynucleotide complementary to the messenger ribonucleic acid of deoxyribonucleic acid topoisomerase II alpha.
Kuriyama M; Tsutsui K; Tsutsui K; Ono Y; Tamiya T; Matsumoto K; Furuta T; Ohmoto T
Neurol Med Chir (Tokyo); 1997 Sep; 37(9):655-61; discussion 661-2. PubMed ID: 9330528
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of topoisomerase IIbeta in poly(ADP-ribose) polymerase-deficient cells.
Canitrot Y; de Murcia G; Salles B
Nucleic Acids Res; 1998 Nov; 26(22):5134-8. PubMed ID: 9801310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
